

Pellegrino Musto

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8749773/pellegrino-musto-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

296
papers

14,874
citations

60
h-index

115
g-index

314
ext. papers

17,204
ext. citations

5.5
avg, IF

5.64
L-index

#	Paper	IF	Citations
296	FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches.. <i>Blood Reviews</i> , 2022 , 100928	11.1	1
295	Management of infectious risk of daratumumab therapy in multiple myeloma: a consensus-based position paper from an ad hoc Italian expert panel.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 172, 103623	7	0
294	The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells.. <i>Diagnostics</i> , 2022 , 12,	3.8	1
293	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101217	2.2	2
292	Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link?. <i>Frontiers in Oncology</i> , 2022 , 12, 873896	5.3	0
291	Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	
290	Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine is not influenced by ABO blood group in subjects with transfusion-dependent thalassemia.. <i>Acta Biomedica</i> , 2022 , 93, e2022134	3.2	0
289	Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients. <i>British Journal of Haematology</i> , 2021 ,	4.5	4
288	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (COMPELL). <i>Journal of Clinical Oncology</i> , 2021 , 39, 3795-3804	21.7	15
287	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021 , 11, 192	7	10
286	From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. <i>Frontiers in Oncology</i> , 2021 , 11, 752192	5.3	0
285	Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. <i>Cancer</i> , 2021 , 127, 2015-2024	6.4	0
284	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021 , 11, 73	7	3
283	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. <i>Clinical Cancer Research</i> , 2021 , 27, 3695-3703	12.9	1
282	Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma. <i>International Journal of Nanomedicine</i> , 2021 , 16, 3141-3160	7.3	10
281	gene alterations characterized by allelic preference in adult acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 1-5	1.9	0
280	Hypereosinophilia with a pinch of salt and pepper. <i>EJHaem</i> , 2021 , 2, 665-666	0.9	

279	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. <i>Haematologica</i> , 2021 , 106, 1079-1085	6.6	8
278	Nanopore sequencing sheds a light on the gene mutations complexity in acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1219-1225	1.9	3
277	What Is New in the Treatment of Smoldering Multiple Myeloma?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
276	Tumor Cell Microenvironment and Microvessel Density Analysis in MALT Type Lymphoma. <i>Anticancer Research</i> , 2021 , 41, 1291-1297	2.3	1
275	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021 , 106, 2799-2812	6.6	4
274	The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 213-218.e3		1
273	Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?. <i>Cancers</i> , 2021 , 13,	6.6	1
272	Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2021 , 11, 17668	4.9	1
271	SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma.. <i>Blood Cancer Journal</i> , 2021 , 11, 201	7	1
270	IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis.. <i>Experimental Hematology and Oncology</i> , 2021 , 10, 58	7.8	0
269	Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick.. <i>Biomarker Research</i> , 2021 , 9, 89	8	0
268	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. <i>Blood Cancer Journal</i> , 2020 , 10, 58	7	3
267	Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses. <i>Expert Review of Hematology</i> , 2020 , 13, 331-349	2.8	11
266	Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for Allele Mutational Burden Assessment in Myeloproliferative Neoplasms: A Retrospective Study. <i>Diagnostics</i> , 2020 , 10,	3.8	3
265	Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity. <i>Blood</i> , 2020 , 136, 12-13	2.2	9
264	Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients. <i>Leukemia Research</i> , 2020 , 88, 106267	2.7	3
263	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. <i>Lancet Haematology,the</i> , 2020 , 7, e861-e873	14.6	19
262	Inflammatory Cells in Diffuse Large B Cell Lymphoma. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10

261	Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned. <i>Frontiers in Oncology</i> , 2020 , 10, 1439	5.3	21
260	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020 , 7, e737-e745	14.6	223
259	Advances in Wadd. Extract Research: In Vitro Antioxidant Activity, Antiproliferative Effects on Acute Myeloid Leukemia Cells and Bioactive Compound Characterization. <i>Molecules</i> , 2020 , 25,	4.8	3
258	SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. <i>HemaSphere</i> , 2020 , 4, e483	0.3	2
257	The Role of Autoimmune Diseases in the Prognosis of Lymphoma. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
256	Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment. <i>Cancers</i> , 2020 , 12,	6.6	5
255	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020 , 105, 193-200	6.6	12
254	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020 , 105, 1074-1080	6.6	13
253	Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence. <i>Expert Review of Hematology</i> , 2020 , 13, 501-517	2.8	3
252	Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis. <i>Cancer Medicine</i> , 2019 , 8, 7567-7576	4.8	3
251	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 4	22.4	16
250	Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells. <i>Stem Cell Research and Therapy</i> , 2019 , 10, 171	8.3	5
249	DNA methylation dynamic of bone marrow hematopoietic stem cells after allogeneic transplantation. <i>Stem Cell Research and Therapy</i> , 2019 , 10, 138	8.3	8
248	An update on biology, diagnosis and treatment of primary plasma cell leukemia. <i>Expert Review of Hematology</i> , 2019 , 12, 245-253	2.8	8
247	Once-weekly twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , 2019 , 104, 1640-1647	6.6	16
246	Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study. <i>Haematologica</i> , 2019 , 104, e4-e8	6.6	4
245	A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain. <i>Molecular Cytogenetics</i> , 2019 , 12, 32	2	1
244	Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the Rete Ematologica Pugliese E Basilicata. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3565-3568	1.9	6

243	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019 , 34, 84-94	11.1	19
242	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. <i>Blood</i> , 2019 , 134, 693-693 ^{2.2}		12
241	An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 249-258	3.8	16
240	Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study). <i>Annals of Hematology</i> , 2019 , 98, 361-367	3	1
239	Leg Type Primary Cutaneous Diffuse Large B-Cell Lymphoma. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019 , 35, 378-379	0.7	
238	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019 , 34, 16-25	11.1	10
237	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 253-264	40	131
236	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1357-1366	4.9	6
235	Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?. <i>Oncologist</i> , 2018 , 23, 511-515	5.7	4
234	Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients. <i>British Journal of Haematology</i> , 2018 , 180, 600-602	4.5	1
233	Heavy/light chain ratio for the assessment of minimal residual disease in myeloma patients achieving complete response. <i>British Journal of Haematology</i> , 2018 , 181, 550-552	4.5	2
232	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). <i>Leukemia and Lymphoma</i> , 2018 , 59, 1113-1120	1.9	12
231	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018 , 32, 1883-1898	10.7	58
230	Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies. <i>Stem Cells International</i> , 2018 , 2018, 9863194	5	24
229	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 130, 27-35	7	17
228	MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	48
227	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 533-540	2	7
226	Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2018 , 97, 1767-1774	3	9

225	Evolution of monoclonal antibodies in multiple myeloma. <i>Lancet Oncology, The</i> , 2018 , 19, 1554-1555	21.7	1
224	Global methylation patterns in primary plasma cell leukemia. <i>Leukemia Research</i> , 2018 , 73, 95-102	2.7	9
223	Future in the Past: Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	15
222	Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. <i>British Journal of Haematology</i> , 2017 , 177, 741-750	4.5	16
221	Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia. <i>Cell Death and Disease</i> , 2017 , 8, e2849	9.8	21
220	Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1424-1432	1.9	9
219	Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. <i>American Journal of Hematology</i> , 2017 , 92, 244-250	7.1	14
218	Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. <i>Journal of Immunology Research</i> , 2017 , 2017, 1832968	4.5	14
217	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3279-3289	2.2	361
216	ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems. <i>American Journal of Hematology</i> , 2017 , 92, 1037-1046	7.1	14
215	EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. <i>Cellular Oncology (Dordrecht)</i> , 2017 , 40, 483-496	7.2	9
214	Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1424-1432	1.9	32
213	MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017 , 40, 97-103	7.2	48
212	Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 552-559	1.9	7
211	Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation?. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	30
210	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	16
209	Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	26
208	Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. <i>Oncotarget</i> , 2017 , 8, 5924-5935	3.3	26

207	Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia. <i>Tumor Biology</i> , 2016 , 37, 217-25	2.9	1
206	Primary plasma cell leukemia 2.0: advances in biology and clinical management. <i>Expert Review of Hematology</i> , 2016 , 9, 1063-1073	2.8	12
205	Are maintenance and continuous therapies indicated for every patient with multiple myeloma?. <i>Expert Review of Hematology</i> , 2016 , 9, 743-51	2.8	11
204	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1823-30	1.9	23
203	A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. <i>Oncotarget</i> , 2016 , 7, 65171-65184	3.3	16
202	Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature. <i>Oncotarget</i> , 2016 , 7, 21353-61	3.3	32
201	Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. <i>Oncotarget</i> , 2016 , 7, 12951-61	3.3	24
200	The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. <i>Blood Transfusion</i> , 2016 , 14, 255-61	3.6	14
199	Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role. <i>Journal of Immunology Research</i> , 2016 , 2016, 9271469	4.5	8
198	Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients. <i>Biologics: Targets and Therapy</i> , 2016 , 10, 1-8	4.4	13
197	Gene expression profiling of normal thyroid tissue from patients with thyroid carcinoma. <i>Oncotarget</i> , 2016 , 7, 29677-88	3.3	10
196	A Pyrazolo[3,4-]pyrimidine Compound Reduces Cell Viability and Induces Apoptosis in Different Hematological Malignancies. <i>Frontiers in Pharmacology</i> , 2016 , 7, 416	5.6	7
195	P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. <i>Frontiers in Pharmacology</i> , 2016 , 7, 491	5.6	20
194	MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation. <i>Oncotarget</i> , 2016 , 7, 6676-92	3.3	71
193	Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma. <i>Oncotarget</i> , 2016 , 7, 14814-30	3.3	62
192	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. <i>European Journal of Haematology</i> , 2016 , 96, 344-51	3.8	24
191	The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma). <i>Physica Medica</i> , 2016 , 32, 651-6	2.7	15
190	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016 , 101, e196-9	6.6	13

189	Primary Plasma Cell Leukemia: Identity Card 2016. <i>Current Treatment Options in Oncology</i> , 2016 , 17, 19	5.4	13
188	Unbiased pro-thrombotic features at diagnosis in 977 thrombocytopenic patients with Philadelphia-negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2016 , 46, 18-25	2.7	9
187	Compendium of FAM46C gene mutations in plasma cell dyscrasias. <i>British Journal of Haematology</i> , 2016 , 174, 642-5	4.5	27
186	Serum levels of soluble calreticulin predict for time to first treatment in early chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2016 , 175, 983-985	4.5	5
185	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. <i>European Journal of Haematology</i> , 2016 , 96, 36-45	3.8	6
184	Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2458-9	1.9	2
183	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2863-9	2.2	976
182	High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. <i>Tumor Biology</i> , 2015 , 36, 9739-52	2.9	113
181	Deferasirox chelation therapy in patients with transfusion-dependent MDS: a real-world report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. <i>European Journal of Haematology</i> , 2015 , 95, 52-6	3.8	19
180	European Myeloma Network guidelines for the management of multiple myeloma-related complications. <i>Haematologica</i> , 2015 , 100, 1254-66	6.6	222
179	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3459-66	2.2	104
178	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015 , 125, 2068-74	2.2	426
177	Alliance Against Cancer, the network of Italian cancer centers bridging research and care. <i>Journal of Translational Medicine</i> , 2015 , 13, 360	8.5	8
176	Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. <i>Stem Cell Research and Therapy</i> , 2015 , 6, 64	8.3	14
175	The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells. <i>British Journal of Haematology</i> , 2015 , 170, 236-46	4.5	28
174	Acquired hemophilia a successfully treated with rituximab. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015 , 7, e2015024	3.2	3
173	Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 17514-34	6.3	18
172	Achievement of European standards by CROB-IRCCS. <i>Tumori</i> , 2015 , 101 Suppl 1, S47-50	1.7	2

171	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. <i>Oncotarget</i> , 2015 , 6, 17543-58	3.3	45
170	Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1510-3	1.9	5
169	Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score. <i>Blood</i> , 2015 , 126, 2554-2554	2.2	2
168	Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. <i>Oncotarget</i> , 2015 , 6, 24205-17	3.3	55
167	A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. <i>Oncotarget</i> , 2015 , 6, 26129-41	3.3	30
166	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. <i>American Journal of Hematology</i> , 2014 , 89, 355-62	7.1	17
165	MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. <i>British Journal of Haematology</i> , 2014 , 164, 841-50	4.5	18
164	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , 2014 , 15, 333-42	21.7	206
163	Validation of vacuum-based refrigerated system for biobanking tissue preservation: analysis of cellular morphology, protein stability, and RNA quality. <i>Biopreservation and Biobanking</i> , 2014 , 12, 35-45	2.1	10
162	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. <i>Journal of Clinical Oncology</i> , 2014 , 32, 634-40	2.2	171
161	Autologous transplantation and maintenance therapy in multiple myeloma. <i>New England Journal of Medicine</i> , 2014 , 371, 895-905	59.2	539
160	Darier sign and cutaneous involvement in mastocytosis. <i>British Journal of Haematology</i> , 2014 , 167, 440	4.5	1
159	Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy. <i>OncoTargets and Therapy</i> , 2014 , 7, 1043-50	4.4	7
158	Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. <i>Blood</i> , 2014 , 124, 63-9	2.2	114
157	Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. <i>Haematologica</i> , 2014 , 99, 1611-7	6.6	16
156	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2014 , 99, 489-96	6.6	46
155	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> , 2014 , 99, 984-96	6.6	86
154	More on spontaneous regression of chronic lymphocytic leukemia: two new cases and potential role of lamivudine in a further patient with advanced disease and hepatitis B virus infection. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1955-7	1.9	

153	F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2014 , 92, 382-9	3.8	56
152	Selected case from the Arkadi M. Rywlin international pathology slide series: lymphangiomatosis of the spleen associated with ipsilateral abdominopelvic and lower extremity venolymphatic malformations: a case report and review of the literature. <i>Advances in Anatomic Pathology</i> , 2014 , 21, 221-28	5.1	3
151	Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. <i>Clinical Cancer Research</i> , 2014 , 20, 6398-405	12.9	69
150	Fournier® gangrene complicating thrombocytopenia treated with steroids. <i>Lancet, The</i> , 2014 , 383, 1580-40	4.0	2
149	Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. <i>Leukemia and Lymphoma</i> , 2014 , 55, 841-7	1.9	15
148	Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study. <i>Blood</i> , 2014 , 124, 2110-2110	2.2	5
147	Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. <i>Hematological Oncology</i> , 2013 , 31, 103-9	1.3	44
146	Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms. <i>BMC Cancer</i> , 2013 , 13, 348	4.8	3
145	Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. <i>Annals of Hematology</i> , 2013 , 92, 1503-11	3	13
144	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013 , 92, 179-83	3	8
143	Treatment of elderly patients with chronic lymphocytic leukemia: an unmet clinical need. <i>Expert Review of Hematology</i> , 2013 , 6, 441-9	2.8	4
142	Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1786-7	1.9	7
141	Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study. <i>American Journal of Hematology</i> , 2013 , 88, 539-44	7.1	7
140	Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. <i>American Journal of Hematology</i> , 2013 , 88, 16-23	7.1	48
139	Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2013 , 37, 520-30	2.7	15
138	Modification of QRS pattern in a patient with AL amyloidosis. <i>International Journal of Cardiology</i> , 2013 , 164, e9-e12	3.2	
137	Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013 , 160, 207-15	4.5	51
136	Fournier® Gangrene Complicating Hematologic Malignancies: a Case Report and Review of Litterature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013 , 5, e2013067	3.2	11

135	Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2013 , 90, 345-8	3.8	35
134	High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. <i>Leukemia and Lymphoma</i> , 2013 , 54, 658-61	1.9	45
133	Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. <i>Clinical Cancer Research</i> , 2013 , 19, 3247-58	12.9	40
132	What is better for older patients with acute myeloid leukemia?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 820-1	2.2	3
131	Cardiovascular events and intensity of treatment in polycythemia vera. <i>New England Journal of Medicine</i> , 2013 , 368, 22-33	59.2	506
130	Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. <i>Clinical Cancer Research</i> , 2013 , 19, 3130-42	12.9	76
129	No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. <i>Blood</i> , 2013 , 121, 1240-2	2.2	19
128	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013 , 122, 3759-66	2.2	63
127	Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. <i>Haematologica</i> , 2013 , 98, 239-46	6.6	197
126	Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. <i>Haematologica</i> , 2013 , 98, 399-403	6.6	28
125	Autoimmune cytopenias in chronic lymphocytic leukemia. <i>Clinical and Developmental Immunology</i> , 2013 , 2013, 730131		9
124	Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?. <i>American Journal of Blood Research</i> , 2013 , 3, 52-7	1.6	17
123	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. <i>Blood</i> , 2013 , 122, 3126-3126	2.2	1
122	Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. <i>Tumori</i> , 2013 , 99, 293e-8e	1.7	3
121	Primary plasma cell leukemia in the era of new drugs: has something changed?. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 82, 141-9	7	17
120	FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. <i>Leukemia Research</i> , 2012 , 36, 37-41	2.7	4
119	Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia. <i>British Journal of Haematology</i> , 2012 , 157, 497-8	4.5	12
118	Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2012 , 158, 426-9	4.5	70

117	Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. <i>Cancer</i> , 2012 , 118, 1014-22	6.4	96
116	Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. <i>Cancer</i> , 2012 , 118, 1574-84	6.4	79
115	A pilot characterization of human lung NSCLC by protein pathway activation mapping. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1755-1766	8.9	19
114	Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2012 , 120, 9-19	2.2	277
113	Outcome of therapy-related myeloid neoplasms treated with azacitidine. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 44	22.4	37
112	A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012 , 87, 628-31	7.1	29
111	Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. <i>Cancer</i> , 2012 , 118, 3954-61	6.4	18
110	Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 505-12	2.8	20
109	An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012 , 156, 481-9	4.5	14
108	Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012 , 4, e2012053	3.2	11
107	Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?. <i>Journal of Clinical Oncology</i> , 2012 , 30, e327-30	2.2	8
106	Quality of life and physicians' perception in myelodysplastic syndromes. <i>American Journal of Blood Research</i> , 2012 , 2, 136-47	1.6	34
105	Using rHuG-CSF in Multiple Myeloma: Consolidated Data, Evolutions, and New Concepts 2012 , 211-223		
104	How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 779-93	5.9	7
103	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. <i>Blood</i> , 2011 , 118, 1239-47	2.2	216
102	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. <i>Blood</i> , 2011 , 117, 3025-31	2.2	207
101	Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. <i>British Journal of Haematology</i> , 2011 , 153, 351-7	4.5	17
100	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. <i>Leukemia Research</i> , 2011 , 35, 1164-9	2.7	25

99	BRAF mutations in hairy-cell leukemia. <i>New England Journal of Medicine</i> , 2011 , 364, 2305-15	59.2	791
98	Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. <i>Journal of Proteome Research</i> , 2011 , 10, 3089-97	5.6	30
97	Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. <i>Leukemia Research</i> , 2011 , 35, 504-7	2.7	11
96	Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. <i>Leukemia Research</i> , 2011 , 35, 566-70	2.7	48
95	Cytological and histological detection of amyloid deposits in bone marrow of patients affected by multiple myeloma. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2304-7	1.9	16
94	A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1942-8	1.9	27
93	Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. <i>Blood</i> , 2011 , 118, 5759-66	2.2	31
92	90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 891-5	8.9	4
91	Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3016-22	149	
90	Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. <i>Leukemia and Lymphoma</i> , 2011 , 52, 771-5	1.9	72
89	Employment of oligodeoxynucleotide plus interleukin-2 improves cytogenetic analysis in splenic marginal zone lymphoma. <i>Journal of Biomedicine and Biotechnology</i> , 2011 , 2011, 691493		7
88	The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi. <i>Blood</i> , 2011 , 118, 2651-2651	2.2	
87	APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS. <i>Blood</i> , 2011 , 118, 1686-1686	2.2	
86	Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. <i>Journal of Clinical Oncology</i> , 2010 , 28, 800-7	2.2	146
85	Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2077-84	2.2	223
84	Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. <i>European Journal of Cancer</i> , 2010 , 46, 420-9	7.5	62
83	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5101-9	2.2	368
82	Melphalan 200 mg/m ² versus melphalan 100 mg/m ² in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. <i>Blood</i> , 2010 , 115, 1873-9	2.2	71

81	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. <i>Blood</i> , 2010 , 116, 4745-53	2.2	325
80	Amyloid in bone marrow smears of patients affected by multiple myeloma. <i>Annals of Hematology</i> , 2010 , 89, 469-74	3	40
79	Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia. <i>Clinical Therapeutics</i> , 2010 , 32, 1911-6	3.5	8
78	Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. <i>European Journal of Haematology</i> , 2010 , 84, 223-8	3.8	62
77	Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. <i>European Journal of Haematology</i> , 2010 , 85, 181-91	3.8	13
76	Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program. <i>Cancer</i> , 2010 , 116, 1485-94	6.4	85
75	Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes. <i>Leukemia Research</i> , 2010 , 34, 981-5	2.7	21
74	Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. <i>Leukemia Research</i> , 2010 , 34, e217-8	2.7	2
73	ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 805-11	2.2	206
72	Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. <i>Clinical Cancer Research</i> , 2009 , 15, 5002-7	12.9	87
71	Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance. <i>Clinical Cancer Research</i> , 2009 , 15, 4439-45	12.9	12
70	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. <i>European Journal of Haematology</i> , 2009 , 82, 93-105	3.8	17
69	Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia. <i>Hematological Oncology</i> , 2009 , 27, 198-202	1.3	10
68	High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. <i>British Journal of Haematology</i> , 2009 , 144, 169-75	4.5	91
67	First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) multiple myeloma working party perspective. <i>Current Drug Targets</i> , 2009 , 10, 906-22	3	6
66	Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.. <i>Blood</i> , 2009 , 114, 128-128	2.2	7
65	Role of thalidomide in previously untreated patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 1569-80	3.5	4
64	Lenalidomide and its role in the management of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 865-74	3.5	14

63	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. <i>Blood</i> , 2008 , 112, 3107-14	2.2	293
62	Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISEL cohort study. <i>Haematologica</i> , 2008 , 93, 1335-42	6.6	31
61	Advanced mast cell disease: an Italian Hematological Multicenter experience. <i>International Journal of Hematology</i> , 2008 , 88, 483-488	2.3	35
60	A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. <i>Cancer</i> , 2008 , 113, 1588-95	6.4	144
59	Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. <i>Leukemia Research</i> , 2008 , 32, 1637-8	2.7	33
58	A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection. <i>Blood</i> , 2008 , 112, 3054-3054	2.2	
57	Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2007 , 48, 56-64	1.9	74
56	Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. <i>Blood</i> , 2007 , 109, 2767-72	2.2	156
55	Melphalan: old and new uses of a still master drug for multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 1467-87	5.9	13
54	Thalidomide therapy in adult patients with myelodysplastic syndrome: a north central cancer treatment group phase II trial. <i>Cancer</i> , 2007 , 109, 1211-2; author reply 1212	6.4	6
53	Efficacy and safety of bortezomib in patients with plasma cell leukemia. <i>Cancer</i> , 2007 , 109, 2285-90	6.4	71
52	Peg-filgrastim versus filgrastim after autologous stem cell transplantation: case-control study in patients with multiple myeloma and review of the literature. <i>Leukemia Research</i> , 2007 , 31, 1487-93	2.7	13
51	Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. <i>British Journal of Haematology</i> , 2007 , 138, 77-81	4.5	66
50	Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. <i>European Journal of Haematology</i> , 2007 , 79, 53-8	3.8	60
49	Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4459-65	2.2	276
48	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. <i>Lancet</i> , 2006 , 367, 825-31	4.0	691
47	Intermediate-dose melphalan (100 mg/m ²)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006 , 6, 475-7		17
46	Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. <i>Leukemia Research</i> , 2006 , 30, 283-5	2.7	15

45	Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2006 , 30, 385-8	2.7	15
44	Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy.. <i>Blood</i> , 2006 , 108, 2442-2442	2.2	
43	High prevalence of hepatitis B virus infection in B-cell non-Hodgkin@ lymphoma. <i>Haematologica</i> , 2006 , 91, 554-7	6.6	100
42	Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. <i>Lancet, The</i> , 2005 , 366, 318-20	4.0	44
41	Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes. <i>Clinical Lymphoma and Myeloma</i> , 2005 , 6, 52-5		4
40	Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2005 , 128, 204-9	4.5	81
39	Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. <i>European Journal of Haematology</i> , 2005 , 75, 391-5	3.8	32
38	Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. <i>Cancer</i> , 2005 , 104, 1428-33	6.4	70
37	Recombinant Erythropoietin and Survival in Myelodysplastic Syndromes.. <i>Blood</i> , 2005 , 106, 2539-2539	2.2	2
36	Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1219-22	1.9	20
35	Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases. <i>Leukemia and Lymphoma</i> , 2004 , 45, 735-8	1.9	28
34	Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. <i>The Hematology Journal</i> , 2004 , 5, 318-24		111
33	Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. <i>Leukemia Research</i> , 2004 , 28, 325-32	2.7	56
32	Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. <i>Leukemia Research</i> , 2004 , 28, 421-2	2.7	24
31	Imatinib-mesylate for all patients with hypereosinophilic syndrome?. <i>Leukemia Research</i> , 2004 , 28, 773-42.7		4
30	Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. <i>Blood</i> , 2004 , 104, 3052-7	2.2	271
29	A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity. <i>Haematologica</i> , 2004 , 89, 1534-6	6.6	10
28	Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1545-8	1.9	37

27	Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. <i>Blood</i> , 2003 , 102, 996-9	2.2	247
26	Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2003 , 122, 269-71	4.5	32
25	Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. <i>British Journal of Haematology</i> , 2003 , 123, 746-7	4.5	21
24	Pamidronate for early-stage, untreated myeloma. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3177-8; author reply 3178	2.2	10
23	Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1545-1548	1.9	21
22	Hepatitis C virus infection and B-cell non-Hodgkin lymphomas: more than a simple association. <i>Clinical Lymphoma and Myeloma</i> , 2002 , 3, 150-60		29
21	Is the scoring system an effective clinico-biological tool in myeloid antigen positive adult acute lymphoblastic leukemia? Results of a long-term study. <i>The Hematology Journal</i> , 2002 , 3, 251-8		3
20	Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. <i>Haematologica</i> , 2002 , 87, 322-3	6.6	10
19	Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2002 , 87, 408-14	6.6	70
18	Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. <i>Haematologica</i> , 2002 , 87, 846-50	6.6	66
17	Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. <i>Haematologica</i> , 2002 , 87, 884-6	6.6	30
16	Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2001 , 114, 78-83	4.5	75
15	Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. <i>Blood</i> , 2001 , 97, 1063-9	2.2	69
14	Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. <i>American Journal of Hematology</i> , 2000 , 64, 275-81	7.1	81
13	Inability of activated cord blood T lymphocytes to perform Th1-like and Th2-like responses: implications for transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 1999 , 8, 381-5		13
12	The role of bisphosphonates for the treatment of bone disease in multiple myeloma. <i>Leukemia and Lymphoma</i> , 1998 , 31, 453-62	1.9	10
11	Serum Level of the Soluble Form of the CD30 Molecule Identifies Patients With Hodgkin Disease at High Risk of Unfavorable Outcome. <i>Blood</i> , 1998 , 91, 3011-3016	2.2	79
10	Conventional induction treatments do not influence overall survival in multiple myeloma. <i>British Journal of Haematology</i> , 1997 , 96, 333-7	4.5	16

9	Plasma cell acid phosphatase and prognosis in multiple myeloma. <i>Leukemia and Lymphoma</i> , 1994 , 14, 497-501	1.9	2
8	Spontaneous remission in acute myeloid leukaemia: a role for endogenous production of tumour necrosis factor and interleukin-2?. <i>British Journal of Haematology</i> , 1994 , 87, 879-80	4.5	34
7	Soluble transferrin receptor in beta-thalassaemia. <i>Lancet, The</i> , 1993 , 342, 1058	4.0	9
6	Increased risk of neurological relapse in acute lymphoblastic leukemias with high levels of cerebrospinal fluid thymidine kinase at diagnosis. <i>Leukemia and Lymphoma</i> , 1993 , 9, 121-4	1.9	1
5	Myelomatous nodular lesions of the liver: diagnosis by ultrasound-guided fine-needle biopsy. <i>Journal of Clinical Ultrasound</i> , 1993 , 21, 133-7	1	10
4	Treatment of plasma cell leukaemia and resistant/relapsed multiple myeloma with vincristine, mitoxantrone and dexamethasone (VMD protocol). <i>British Journal of Haematology</i> , 1991 , 79, 655-6	4.5	7
3	Clinical Relevance of Immunocytochemical Detection of Multidrug-Resistance-Associated P-Glycoprotein in Hematologic Malignancies. <i>Tumori</i> , 1990 , 76, 353-359	1.7	17
2	Significance and limits of cerebrospinal fluid beta-2-microglobulin measurement in course of acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 1988 , 28, 213-8	7.1	3
1	Serum Beta2-Microglobulin in Malignant Lymphoproliferative Disorders. <i>Tumori</i> , 1988 , 74, 129-135	1.7	15